LUMO stock information

Sector:

Healthcare

Description:

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Lumos Pharma, Inc. website

Current Price

$3.88

RSI

63.43

Market Capitalization:

75.2M

Beta:

None

Volume:

20,008

Analyst Target Price:

$ 27.17

Economiic Fair Price:

Earnings DateNovember 01, 2022

Report DateAugust 10, 2022

QuarterQ2

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend

Dividend Rate N/A

Payout Ratio N/A

Cash79.5M

Debt395000

EPS-3.267

Profit MarginN/A

Revenue Per Share TTM0.006

Return On Equity TTM-0.256

YoY Revenue Growth (TTM)

YoY Pre Tax Income Growth (TTM)

-138.05 %

YoY Free Cash Flow (TTM)

QoQ Revenue Growth

3930.00 %

QoQ Pre Tax Income Growth

9.53 %

QoQ Free Cash Flow Growth

-139.50 %

2021 Revenue

$ 230.00

-99.86 %

2020 Revenue

$ 168K

-82.05 %

2019 Revenue

$ 936K

-92.50 %

2018 Revenue

$ 12.5M

-56.55 %

2017 Revenue

$ 28.7M

-19.73 %

2016 Revenue

$ 35.8M

2020 Free Cash Flow

$ -23M

2019 Free Cash Flow

$ -30.2M

2018 Free Cash Flow

$ -37.9M

2017 Free Cash Flow

$ -48.3M

2016 Free Cash Flow

$ -68.2M

2021 Pre Tax Income

$ -29.8K

99.85 %

2020 Pre Tax Income

$ -19.6M

54.31 %

2019 Pre Tax Income

$ -43M

29.04 %

2018 Pre Tax Income

$ -60.6M

16.48 %

2017 Pre Tax Income

$ -72.5M

19.89 %

2016 Pre Tax Income

$ -90.5M

Lumos Pharma, Inc.(LUMO)